Mercado de medicamentos para a pneumonia adquirida pela comunidade da Índia – Tendências e previsões do setor para 2031

Análise e insights do mercado de medicamentos para a pneumonia adquirida pela comunidade da Índia

Um dos principais fatores que impulsionam o crescimento do mercado é a crescente prevalência da pneumonia. Além disso, o aumento da consciencialização e o aumento dos gastos em saúde são outro fator importante para o crescimento do mercado. No entanto, a acessibilidade e a sensibilidade ao preço associadas aos medicamentos estão a restringir o crescimento do mercado. Espera-se que as soluções impulsionadas pela tecnologia e pela inovação funcionem como uma oportunidade para o crescimento do mercado. No entanto, as infraestruturas e o acesso limitados aos cuidados de saúde podem criar um desafio ao crescimento do mercado.

A Data Bridge Market Research analisa que o mercado indiano de medicamentos para a pneumonia adquiridos pela comunidade deverá atingir os 163,52 milhões de dólares até 2031, face aos 92,72 milhões de 2023, crescendo com um CAGR de 7,5% no período previsto de 2024 a 2031.

Definição de mercado

A pneumonia adquirida na comunidade (PAC) refere-se a um tipo de pneumonia adquirida fora dos hospitais ou unidades de saúde. É uma doença infecciosa comum caracterizada por inflamação do tecido pulmonar devido à infeção por bactérias, vírus, fungos ou outros agentes patogénicos. A PAC afeta indivíduos de todas as idades, mas é particularmente prevalente em crianças, idosos e indivíduos com problemas de saúde subjacentes ou sistema imunitário comprometido.

Dinâmica do mercado de medicamentos para a pneumonia adquirida pela comunidade da Índia

This section deals with understanding the market drivers, opportunities, restraints, and challenges. All of this is discussed in detail below:     

Driver

• Rising Prevalence of Pneumonia

The rising prevalence and burden of pneumonia in India present a substantial opportunity for the Community-Acquired Pneumonia (CAP) drug market in the country. With pneumonia being a leading cause of morbidity and mortality, particularly among vulnerable populations such as children and the elderly, there is an increasing demand for effective and accessible treatments. This heightened need creates a market opportunity for pharmaceutical companies to innovate, develop, and provide a diverse range of pneumonia drugs tailored to address the evolving strains and challenges associated with the disease.

• Growing Antibiotic Resistance Pathogen Causing Pneumonia

The growing rate of antibiotic-resistant pathogens causing pneumonia presents a unique feature for the Community-Acquired Pneumonia (CAP) drug market in India. There is an urgent need for innovative and effective treatments to combat evolving microbial threats, as antibiotic resistance becomes a global concern. India, with its thriving pharmaceutical industry, has the potential to lead in the development of new antibiotics and alternative therapies. Indian pharmaceutical companies can contribute valuable solutions to the global healthcare landscape by investing in research and development to address antibiotic-resistant strains. In addition, initiatives that prioritize research on antibiotic stewardship and combination therapies can further enhance India standing in addressing the complex issue of antibiotic resistance in pneumonia treatment.

Opportunity

• Technology-Driven Solutions and Innovation

Leveraging advanced technologies, such as artificial intelligence, data analytics, and telemedicine, can streamline various aspects of the healthcare system. This includes improved diagnostic capabilities, personalized treatment plans, and efficient supply chain management for pneumonia drugs. In addition, innovative approaches in drug development, such as novel formulations or drug delivery systems, can enhance the efficacy and patient adherence to treatments. The adoption of digital platforms for healthcare services, including remote patient monitoring and virtual consultations, can overcome geographical barriers, ensuring that even rural populations have access to timely medical interventions. Embracing technology not only enhances the overall efficiency of healthcare delivery but also positions India as a leader in healthcare innovation, contributing to the advancement of the CAP drug market both domestically and on the global stage. This convergence of technology and healthcare presents an opportunity for India to create a more resilient, accessible, and patient-centric market.

Restraints/Challenges

• Affordability and Price Sensitivity Associated with the Drugs

With a diverse socioeconomic landscape and a large population facing varying levels of financial constraints, the cost of medications becomes a critical factor in healthcare access. Pneumonia, as a prevalent respiratory infection, necessitates timely and effective treatment, but the financial burden associated with pharmaceuticals can hinder patients from seeking necessary medications promptly. Price sensitivity among the population, coupled with the high prevalence of CAP, poses challenges for pharmaceutical companies to strike a balance between offering quality drugs and ensuring they are economically viable for a broad segment of the population. The affordability constraint may lead to delayed or inadequate treatment, impacting health outcomes and potentially contributing to the persistence of pneumonia-related morbidity and mortality in India.

• Limited Healthcare Infrastructure and Access

The lack of accessible healthcare services makes it difficult for individuals to receive timely and quality medical care, including diagnosis and treatment for various health conditions.

This limitation in infrastructure and access can lead to delayed medical interventions, exacerbation of health issues, and a higher burden of preventable diseases. Individuals may face challenges in reaching healthcare facilities promptly, obtaining necessary diagnostic tests, and accessing appropriate pneumonia drugs.

Recent Developments

• In September 2023, Astrazeneca has received an approval from the Central Drugs Standard Control Organisation (CDSCO) to import and market a medication to prevent Respiratory Syncytial virus. This will help the company to strengthen its presence in India market
• In May 2021, Teva Pharmaceutical Industries Ltd. announced the launch of its 250 mg and 500 mg strength generic Erythromycin tablets—a therapeutic equivalent for the Reference Listed Drug (RLD) Erythromycin Tablets from Arbor Pharmaceuticals. This has helped the company to strengthen its product portfolio

India Community Acquired Pneumonia Drugs Market Scope

The India community acquired pneumonia drugs market is segmented into nine notable segments based on product, route of administration, dosage, product type, mode of purchase, type, population type, end user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the differences in your target markets.

Product

• Macrolides
• B-Lactam Antibiotics
• Quinolones
• Tetracycline
• Carbapenem
• Glycopeptide Antibiotics
• Pleuromutilin
• Others

On the basis of product, the market is segmented into macrolides, B-lactam antibiotics, quinolones, tetracycline, carbapenem, glycopeptide antibiotics, pleuromutilin, and others.

Route of Administration

• Oral
• Intravenous

On the basis of route of administration, the market is segmented into oral and intravenous.

Dosage

• Tablet
• Solution

On the basis of dosage, the market is segmented into tablet and solution.

Product Type

• Genéricos
•  Com marca

Com base no tipo de produto, o mercado está segmentado em genéricos e de marca.

Modo de compra

• Prescrição
•  OTC

Com base no modo de compra, o mercado está segmentado em prescrição e OTC.

Tipo

• Bacteriana
• Vírus
• Fungos

Com base no tipo, o mercado está segmentado em bactérias, vírus e fungos.

Tipo de população

• Crianças
•  Geriatria
•  Adultos

Com base no tipo populacional, o mercado está segmentado em crianças, geriatria e adultos.

Utilizador final

• Hospitais
•  Clínicas Especializadas
•  Cuidados domiciliários
•  Outros

Com base no utilizador final, o mercado está segmentado em hospitais, clínicas especializadas, homecare, entre outros.

Canal de distribuição

• Farmácia Hospitalar
•  Farmácia de Retalho
•  Farmácia on-line
•  Outros

Com base no canal de distribuição, o mercado está segmentado em farmácia hospitalar, farmácia de retalho, farmácia online, entre outros.

Cenário competitivo do mercado de medicamentos para a pneumonia adquirida pela comunidade da Índia e análise de ações

O panorama competitivo do mercado de medicamentos para a pneumonia adquiridos pela comunidade indiana fornece detalhes dos concorrentes. Os detalhes incluídos são a visão geral da empresa, finanças da empresa, receitas geradas, potencial de mercado, investimento em I&D, novas iniciativas de mercado, localizações e instalações de produção, pontos fortes e fracos da empresa, lançamento de produtos, aprovações de produtos, largura e amplitude do produto, domínio de aplicação e tipo de produto curva da linha de vida. Os dados fornecidos acima estão apenas relacionados com o foco da empresa no mercado.

Alguns dos principais players do mercado que operam no mercado são a Pfizer Inc., Cipla Inc., AstraZeneca, Abbott, Teva Pharmaceutical Industries Ltd., Novartis AG, Fresenius Kabi, Baxter e Aurobindo Pharma USA, entre outros. 

SKU-70632